292 results on '"Castinetti, Frédéric"'
Search Results
2. Updates on the genetics of multiple endocrine neoplasia
3. Sunitinib for metastatic progressive phaeochromocytomas and paragangliomas: results from FIRSTMAPPP, an academic, multicentre, international, randomised, placebo-controlled, double-blind, phase 2 trial
4. French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines/Association Francophone de Chirurgie Endocrinienne/Reseau national de prise en charge des tumeurs endocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1
5. Pharmacological Treatment of Cushing's Syndrome
6. Position statement on the diagnosis and management of acromegaly: The French National Diagnosis and Treatment Protocol (NDTP)
7. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants
8. Pituitary and adrenal disorders induced by immune checkpoint inhibitors
9. How best to monitor the specific side effects of medical treatments of Cushing’s disease
10. Impact of Cushing's syndrome on fertility and pregnancy
11. Consensus statement by the French Society of Endocrinology (SFE) and French Society of Pediatric Endocrinology & Diabetology (SFEDP) on diagnosis of Cushing's syndrome
12. Plasma Renin: A Useful Marker for Mineralocorticoid Adjustment in Patients With Primary Adrenal Insufficiency.
13. Challenges in molecular diagnosis of multiple endocrine neoplasia.
14. Coexistence of Endocrine Side Effects of Immunotherapy in Clinical Practice
15. Familial hypocalciuric hypercalcemia: the challenge of diagnosis
16. Consensus on diagnosis and management of Cushing's disease: a guideline update
17. Role of growth hormone in hepatic and intestinal triglyceride-rich lipoprotein metabolism
18. Aggressive pituitary tumours and pituitary carcinomas
19. The risks of medical treatment of prolactinoma
20. Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives
21. Fluctuation analysis of postoperative secretory status in patients operated for acromegaly
22. Comparison of 68Ga-Dotatate PET/CT and 18F-FDOPA PET/CT for the diagnosis of pancreatic neuroendocrine tumors in a MEN1 patient
23. Surgical indications for pituitary tumors during pregnancy: a literature review
24. Physiopathology, Diagnosis, and Treatment of Nonfunctioning Pituitary Adenomas
25. Large Adrenal Incidentalomas Require a Dedicated Diagnostic Procedure
26. Endocrinopathies induites par l’immunothérapie : synthèse du consensus 2018 de la Société française d’endocrinologie
27. Functioning gonadotroph adenoma with severe ovarian hyperstimulation syndrome: A new emergency in pituitary adenoma surgery? Surgical considerations and literature review
28. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study
29. Genetic testing in prolactinomas: a cohort study
30. Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET
31. French guidelines from the GTE, AFCE and ENDOCAN-RENATEN (Groupe d’étude des Tumeurs Endocrines / Association Française de Chirurgie Endocrinienne / REseau NAtional de prise en charge des Tumeurs ENdocrines) for the screening, diagnosis and management of Multiple Endocrine Neoplasia Type 1
32. Endocrine side-effects of new anticancer therapies: Overall monitoring and conclusions
33. Introduction to expert opinion on endocrine complications of new anticancer therapies
34. Phéochromocytomes et paragangliomes génétiquement déterminés: quelle conduite à tenir chez les apparentés ?
35. Genes important in the fetal development of the pituitary
36. Characterization of adrenocortical tumors by 18F-FDG PET/CT: Does steroid hormone hypersecretion status modify the uptake pattern?
37. SFE/SFEDP adrenal insufficiency French consensus: Introduction and handbook
38. Early 18F-FDOPA PET/CT imaging after carbidopa premedication as a valuable diagnostic option in patients with insulinoma
39. Group 4: Replacement therapy for adrenal insufficiency
40. Editorial: Cardiac fat in metabolic and endocrine diseases
41. Combined Pituitary Hormone Deficiency
42. Lessons from monogenic causes of growth hormone deficiency
43. Long-term outcome of macroprolactinomas
44. Clinical consensus guideline on the management of phaeochromocytoma and paraganglioma in patients harbouring germline SDHD pathogenic variants
45. Complications Related to the Endoscopic Endonasal Transsphenoidal Approach for Nonfunctioning Pituitary Macroadenomas in 300 Consecutive Patients
46. Non-functioning pituitary adenoma: When and how to operate? What pathologic criteria for typing?
47. Management of clinically non-functioning pituitary adenoma
48. An observational study on adrenal insufficiency in a French tertiary centre: Real life versus theory
49. Efficacy and Safety of Osilodrostat in Paraneoplastic Cushing Syndrome: A Real-World Multicenter Study in France
50. Corticotroph tumor progression after bilateral adrenalectomy: data from ERCUSYN
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.